Warner Chilcott
Upgrade to Premium features
Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market
Get access-
Full access to the largest bond database
Bond parameters,
prospectuses -
Seamless
Data exportAnalyze the data in the most efficient way
-
Bond pricing
Current & historical quotes from 400+ stock exchanges & OTC market
-
Smart risk assessment
Credit ratings, financial reports
Trading Schedule Issuer map
Quotes
- «
- 1
- ...
- {{ quotes.page - 2 }}
- {{ quotes.page - 1 }}
- {{ quotes.page }}
- {{ quotes.page + 1 }}
- {{ quotes.page + 2 }}
- ...
- {{ quotesLastPage }}
- »
Profile
|
Warner Chilcott Public Limited Company is a specialty pharmaceutical company. It is focused on the women’s healthcare, gastroenterology, dermatology and urology segments of the branded pharmaceuticals market, primarily in North America. It is an integrated company with internal resources focused on the development, manufacture and promotion of its products. Its women’s healthcare franchise is anchored by its presence in the hormonal contraceptive, osteoporosis and hormone therapy (HT) markets. The Company’s hormonal contraceptive product offerings include LOESTRIN 24 FE (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets), the branded product in the United States hormonal contraception market, and LO LOESTRIN FE (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets), its new oral contraceptive product that offers women the lowest dosage of estrogen of any oral contraceptive.
|
General information
-
Organization nameWarner Chilcott Plc
-
Organization statusOperating organization
-
Site









